tiprankstipranks
EyePoint Pharmaceuticals Inc (DE:PV3B)
FRANKFURT:PV3B
Germany Market
PV3B
EyePoint Pharmaceuticals
RESEARCH TOOLSreports

EyePoint Pharmaceuticals (PV3B) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

PV3B Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
8 Buy
5 Hold
0 Sell
Based on 13 analysts giving stock ratings to
EyePoint
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PV3B Stock 12 Month Forecast

Average Price Target

€23.32
▲(124.25% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is €23.32 with a high forecast of €58.74 and a low forecast of €4.32. The average price target represents a 124.25% change from the last price of €10.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","17":"€17","31":"€31","45":"€45","59":"€59"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58.73638992,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€58.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.321801880000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.3188522,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,17,31,45,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.9,14.579722301538462,18.259444603076922,21.939166904615384,25.618889206153845,29.298611507692307,32.97833380923077,36.65805611076923,40.33777841230769,44.017500713846154,47.697223015384616,51.37694531692308,55.05666761846154,{"y":58.73638992,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.9,11.855523221538462,12.811046443076924,13.766569664615385,14.722092886153847,15.677616107692309,16.633139329230772,17.588662550769232,18.544185772307692,19.499708993846156,20.45523221538462,21.41075543692308,22.36627865846154,{"y":23.321801880000002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.9,10.393757861538463,9.887515723076923,9.381273584615386,8.875031446153846,8.368789307692309,7.86254716923077,7.3563050307692315,6.850062892307693,6.343820753846154,5.837578615384616,5.331336476923077,4.82509433846154,{"y":4.3188522,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.238,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.536,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.665,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.165,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.285,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.955,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€58.74Average Price Target€23.32Lowest Price Target€4.32
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on DE:PV3B
Debanjana Chatterjee
JonesTrading
JonesTrading
€37.14→€17.28
Buy
66.11%
Upside
Reiterated
08/18/26
Analyst Maintains Buy on Duravyu, Cutting Price Target to $20 Amid LUCIA Trial Binary Risk
Citi Analyst forecast on DE:PV3B
Yigal Nochomovitz
Citi
Citi
€30.23→€14.68
Buy
41.19%
Upside
Reiterated
08/18/26
EyePoint price target lowered to $17 from $35 at CitiEyePoint price target lowered to $17 from $35 at Citi
Chardan Capital Analyst forecast on DE:PV3B
Andreas Argyrides
Chardan Capital
Chardan Capital
€56.15→€4.32
Hold
-58.47%
Downside
Downgraded
08/18/26
EyePoint downgraded to Neutral from Buy at ChardanEyePoint downgraded to Neutral from Buy at Chardan
H.C. Wainwright Analyst forecast on DE:PV3B
Yi Chen
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Downgraded
08/18/26
EyePoint downgraded to Neutral from Buy at H.C. WainwrightEyePoint downgraded to Neutral from Buy at H.C. Wainwright
Jefferies Analyst forecast on DE:PV3B
Faisal Khurshid
Jefferies
Jefferies
€25.91→€6.91
Buy
-33.56%
Downside
Reiterated
08/17/26
EyePoint price target lowered to $8 from $30 at JefferiesEyePoint price target lowered to $8 from $30 at Jefferies
Mizuho Securities Analyst forecast on DE:PV3B
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
€33.69
Buy
223.91%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Elicio Therapeutics (NASDAQ: ELTX), EyePoint Pharmaceuticals (NASDAQ: EYPT) and LeonaBio (NASDAQ: LONA)
J.P. Morgan Analyst forecast on DE:PV3B
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Hold
―
Downgraded
08/17/26
EyePoint downgraded to Neutral from Overweight at JPMorganEyePoint downgraded to Neutral from Overweight at JPMorgan
Cantor Fitzgerald Analyst forecast on DE:PV3B
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
08/17/26
EyePoint downgraded to Neutral from Overweight at Cantor FitzgeraldEyePoint downgraded to Neutral from Overweight at Cantor Fitzgerald
RBC Capital Analyst forecast on DE:PV3B
Lisa Walter
RBC Capital
RBC Capital
€31.96→€4.32
Hold
-58.47%
Downside
Downgraded
08/17/26
EyePoint downgraded to Sector Perform from Outperform at RBC CapitalEyePoint downgraded to Sector Perform from Outperform at RBC Capital
Laidlaw Analyst forecast on DE:PV3B
Yale Jen
Laidlaw
Laidlaw
€43.19→€41.46
Buy
298.66%
Upside
Reiterated
08/17/26
Laidlaw trims EyePoint target, still sees high change of approvalLaidlaw trims EyePoint target, still sees high change of approval
TD Cowen Analyst forecast on DE:PV3B
Tara Bancroft
TD Cowen
TD Cowen
€17.28
Buy
66.11%
Upside
Reiterated
08/05/26
Analyst Reiterates Buy on EYPT Ahead of Pivotal LUGANO Phase III Data and Favorable Risk‑Reward Profile
Stifel Nicolaus Analyst forecast on DE:PV3B
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
€34.55
Buy
232.22%
Upside
Initiated
07/16/26
EyePoint initiated with a Buy at StifelEyePoint initiated with a Buy at Stifel
Guggenheim Analyst forecast on DE:PV3B
Yatin Suneja
Guggenheim
Guggenheim
€58.74
Buy
464.77%
Upside
Reiterated
06/24/26
Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on DE:PV3B
Debanjana Chatterjee
JonesTrading
JonesTrading
€37.14→€17.28
Buy
66.11%
Upside
Reiterated
08/18/26
Analyst Maintains Buy on Duravyu, Cutting Price Target to $20 Amid LUCIA Trial Binary Risk
Citi Analyst forecast on DE:PV3B
Yigal Nochomovitz
Citi
Citi
€30.23→€14.68
Buy
41.19%
Upside
Reiterated
08/18/26
EyePoint price target lowered to $17 from $35 at CitiEyePoint price target lowered to $17 from $35 at Citi
Chardan Capital Analyst forecast on DE:PV3B
Andreas Argyrides
Chardan Capital
Chardan Capital
€56.15→€4.32
Hold
-58.47%
Downside
Downgraded
08/18/26
EyePoint downgraded to Neutral from Buy at ChardanEyePoint downgraded to Neutral from Buy at Chardan
H.C. Wainwright Analyst forecast on DE:PV3B
Yi Chen
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Downgraded
08/18/26
EyePoint downgraded to Neutral from Buy at H.C. WainwrightEyePoint downgraded to Neutral from Buy at H.C. Wainwright
Jefferies Analyst forecast on DE:PV3B
Faisal Khurshid
Jefferies
Jefferies
€25.91→€6.91
Buy
-33.56%
Downside
Reiterated
08/17/26
EyePoint price target lowered to $8 from $30 at JefferiesEyePoint price target lowered to $8 from $30 at Jefferies
Mizuho Securities Analyst forecast on DE:PV3B
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
€33.69
Buy
223.91%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Elicio Therapeutics (NASDAQ: ELTX), EyePoint Pharmaceuticals (NASDAQ: EYPT) and LeonaBio (NASDAQ: LONA)
J.P. Morgan Analyst forecast on DE:PV3B
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Hold
―
Downgraded
08/17/26
EyePoint downgraded to Neutral from Overweight at JPMorganEyePoint downgraded to Neutral from Overweight at JPMorgan
Cantor Fitzgerald Analyst forecast on DE:PV3B
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
08/17/26
EyePoint downgraded to Neutral from Overweight at Cantor FitzgeraldEyePoint downgraded to Neutral from Overweight at Cantor Fitzgerald
RBC Capital Analyst forecast on DE:PV3B
Lisa Walter
RBC Capital
RBC Capital
€31.96→€4.32
Hold
-58.47%
Downside
Downgraded
08/17/26
EyePoint downgraded to Sector Perform from Outperform at RBC CapitalEyePoint downgraded to Sector Perform from Outperform at RBC Capital
Laidlaw Analyst forecast on DE:PV3B
Yale Jen
Laidlaw
Laidlaw
€43.19→€41.46
Buy
298.66%
Upside
Reiterated
08/17/26
Laidlaw trims EyePoint target, still sees high change of approvalLaidlaw trims EyePoint target, still sees high change of approval
TD Cowen Analyst forecast on DE:PV3B
Tara Bancroft
TD Cowen
TD Cowen
€17.28
Buy
66.11%
Upside
Reiterated
08/05/26
Analyst Reiterates Buy on EYPT Ahead of Pivotal LUGANO Phase III Data and Favorable Risk‑Reward Profile
Stifel Nicolaus Analyst forecast on DE:PV3B
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
€34.55
Buy
232.22%
Upside
Initiated
07/16/26
EyePoint initiated with a Buy at StifelEyePoint initiated with a Buy at Stifel
Guggenheim Analyst forecast on DE:PV3B
Yatin Suneja
Guggenheim
Guggenheim
€58.74
Buy
464.77%
Upside
Reiterated
06/24/26
Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

3 Months
Graig SuvannavejhMizuho Securities
Success Rate
12/25 ratings generated profit
48%
Average Return
+3.82%
Copying Graig Suvannavejh's trades and holding each position for 3 Months would result in 48.00% of your transactions generating a profit, with an average return of +3.82% per trade.
1 Year
Yatin SunejaGuggenheim
Success Rate
5/9 ratings generated profit
56%
Average Return
+50.98%
Copying Yatin Suneja's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +50.98% per trade.
2 Years
Yatin SunejaGuggenheim
Success Rate
5/9 ratings generated profit
56%
Average Return
+24.80%
Copying Yatin Suneja's trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +24.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PV3B Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
16
17
13
21
27
Buy
1
2
1
1
0
Hold
0
0
0
0
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
19
14
22
32
In the current month, PV3B has received 27 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. PV3B average Analyst price target in the past 3 months is 23.32.
Each month's total comprises the sum of three months' worth of ratings.

PV3B Financial Forecast

PV3B Earnings Forecast

Next quarter’s earnings estimate for PV3B is -€0.78 with a range of -€0.94 to -€0.52. The previous quarter’s EPS was -€0.94. PV3B beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PV3B has Performed in-line its overall industry.
Next quarter’s earnings estimate for PV3B is -€0.78 with a range of -€0.94 to -€0.52. The previous quarter’s EPS was -€0.94. PV3B beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PV3B has Performed in-line its overall industry.

PV3B Sales Forecast

Next quarter’s sales forecast for PV3B is €200.39K with a range of €0.00 to €496.67K. The previous quarter’s sales results were €437.93K. PV3B beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PV3B has Performed in-line its overall industry.
Next quarter’s sales forecast for PV3B is €200.39K with a range of €0.00 to €496.67K. The previous quarter’s sales results were €437.93K. PV3B beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PV3B has Performed in-line its overall industry.

PV3B Stock Forecast FAQ

What is DE:PV3B’s average 12-month price target, according to analysts?
Based on analyst ratings, EyePoint Pharmaceuticals Inc’s 12-month average price target is 23.32.
    What is DE:PV3B’s upside potential, based on the analysts’ average price target?
    EyePoint Pharmaceuticals Inc has 124.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EyePoint Pharmaceuticals Inc a Buy, Sell or Hold?
          EyePoint Pharmaceuticals Inc has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 5 hold ratings and 0 sell ratings.
            What is EyePoint Pharmaceuticals Inc’s share price target?
            The average share price target for EyePoint Pharmaceuticals Inc is 23.32. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €58.74 ,and the lowest forecast is €4.32. The average share price target represents 124.25% Increase from the current price of €10.4.
              What do analysts say about EyePoint Pharmaceuticals Inc?
              EyePoint Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of EyePoint Pharmaceuticals Inc?
                To buy shares of DE:PV3B, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.